Technological Obsolescence and Intellectual Property Rights Infringement
First written in FY2016. 4 of 6 entries say "Restated". Latest entry: FY2026.
Precision System Science moved to the "Worse" side of this theme in 2026, 2 years after the typical company in this theme (2024).
The whole theme swung hardest in 2020: 4 of 42 companies on the "Worse" side.
3 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「If the Group's intellectual property rights are invalidated or lapse, are infringed by a third party, or if the Group unintentionally infringes a third party's intellectual property rights, resulting in an injunction claim, damages claim or other dispute, the Group's financial condition and operating results may be affected by a decline in competitiveness, restrictions on the development or sale of products, response costs and other factors.」
The description was broadened from a focus on technological obsolescence to intellectual property risks, including invalidation or lapse of rights, infringement by third parties and unintentional infringement. - FY2020RestatedAnnual report
「Accordingly, even if the Group protects its technologies through patents and other means, there is always a risk that a new technological concept relating to DNA extraction, a core product of the Company, for example, may be invented, rendering the Group's patented technology obsolete.」
The risk that existing patents and products will become obsolete as a result of technological innovation remains. No litigation or claims involving third parties had arisen. - FY2019RestatedAnnual report
「New technologies are being developed every day in the gene-related industry. Accordingly, even if the Group protects its technologies through patents and other means, there is always a risk that a new technological concept relating to DNA extraction, a core product of the Company, for example, may be invented, rendering the Group's patented technology obsolete.」
The risk that existing patents and products will become obsolete as a result of technological innovation remains. No litigation or claims involving third parties had arisen. - FY2018RestatedAnnual report
「New technologies are being developed every day in the gene-related industry. Accordingly, even if the Group protects its technologies through patents and other means, there is always a risk that a new technological concept relating to DNA extraction, a core product of PSS, for example, may be invented, rendering the Group's patented technology obsolete.」
The risk that existing patents and products will become obsolete as a result of technological innovation remains. No litigation or claims involving third parties had arisen as of the end of the consolidated fiscal year. - FY2017RestatedAnnual report
「New technologies are being developed every day in the gene-related industry. Accordingly, even if the Group protects its technologies through patents and other means, there is always a risk that a new technological concept relating to DNA extraction, a core product of PSS, for example, may be invented, rendering the Group's patented technology obsolete.」
The risk that existing patents and products will become obsolete as a result of technological innovation remains. The disclosure also states that, as of the end of the consolidated fiscal year, no litigation or claims involving third parties had arisen. - FY2016First statedAnnual report
「New technologies are being developed every day in the gene-related industry. Accordingly, even if the Group protects its technologies through patents and other means, there is always a risk that a new technological concept relating to DNA extraction, a core product of PSS, for example, may be invented, rendering the Group's patented technology obsolete.」
The disclosure describes efforts to establish a competitive advantage through patents, while noting the possibility that existing patents and products may be rendered obsolete by new technologies developed by other companies.